Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

PURPOSE: We report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for RET fusion-positive non–small cell lung cancers (NSCLC). PATIENTS AND METHODS: In the global phase 1/2 LIBRETTO-001 trial (NCT03157128) in advanced RET-altere...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbiah, Vivek, Gainor, Justin F., Oxnard, Geoffrey R., Tan, Daniel S.W., Owen, Dwight H., Cho, Byoung Chul, Loong, Herbert H., McCoach, Caroline E., Weiss, Jared, Kim, Yu Jung, Bazhenova, Lyudmila, Park, Keunchil, Daga, Haruko, Besse, Benjamin, Gautschi, Oliver, Rolfo, Christian, Zhu, Edward Y., Kherani, Jennifer F., Huang, Xin, Kang, Suhyun, Drilon, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447251/
https://www.ncbi.nlm.nih.gov/pubmed/34088726
http://dx.doi.org/10.1158/1078-0432.CCR-21-0800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447251/
https://www.ncbi.nlm.nih.gov/pubmed/34088726
http://dx.doi.org/10.1158/1078-0432.CCR-21-0800

Ejemplares similares